All In Biotech

NDA 209353 · Dow Pharm

Altreno

Tretinoin · Topical · Retinoid

Last checked: Nov 20, 2026Latest source record: Aug 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 23, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

375

82 Phase 3, 25 recruiting

FAERS reports

6,579

4,119 serious, 851 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

ALTRENO ® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. (1)

Mechanism: Tretinoin is a metabolite of vitamin A that binds with high affinity to specific retinoic acid receptors located in both the cytosol and nucleus. Tretinoin activates three members of the retinoic acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors, other mechanisms, or both. Although the exact mode of action of tretinoin in acne treatment is unknown,...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ALTRENO · TRETINOIN 0.05% · LOTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.

All 375 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use877
  • drug ineffective731
  • product use in unapproved indication493
  • pain490
  • vomiting450
  • paraesthesia373
  • abdominal pain upper368
  • rash362
  • nausea351
  • diarrhoea347
  • maternal exposure during pregnancy338
  • headache335

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200531
200624
200739
2008114
200972
201078
201189
2012153
2013100
2014147
2015223
2016342
2017343
2018461
2019356
2020381
2021434
2022514
2023572
2024684
2025819
2026566

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Altreno (Tretinoin)

2024 spending

$92K

Beneficiaries

584

1,009 claims

Per beneficiary

$158

$2.46 per unit

View as table
YearSpending
2020$65,856
2021$78,857
2022$83,039
2023$84,389
2024$92,120

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: Dow Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.